Stocks to watch, March 6: Gensol Engineering, Sterlite Tech, Adani Enterprises, LIC Housing Finance, TCS, RPP Infra, and more

At 7:40 AM, the GIFT NIFTY futures were trading at 22,477, up 21 points, or 0.09%. This implies that the NIFTY50 index will open 35 points higher.

In the overnight trade, Wall Street's main indexes finished higher in choppy trading, as investors cheered the likely easing of trade tensions between the US and major trading partners.

The Dow Jones Industrial Average rose 485.60 points, or 1.14%, to 43,006.59; the S&P 500 gained 64.48 points, or 1.12%, to 5,842.63; and the Nasdaq Composite gained 267.57 points, or 1.46%, to 18,552.73.

The shares were offloaded at an average price of ₹81.04 apiece, taking the deal value to ₹84.10 crore.

In an eight-page order, the Competition Commission of India (CCI) said there is no prima facie case of contravention of either Section 3 or Section 4 of the Competition Act. It dismissed the complaint against the two entities.

The shares were disposed of at an average price of ₹2,168.1 apiece, taking the combined transaction value to ₹1,831.82 crore.

Acknowledging the credit rating downgrades by CARE and ICRA, the firm said that it has happened due to a short-term liquidity mismatch, which is improving by way of customer payments.

"That said, we understand the concerns these downgrades have raised and are committed to addressing them responsibly to all our stakeholders," it said in a statement.

The solution will be available across 23,000 fuel stations of the government-owned oil marketing company, besides over 2,000 authorised outlets of the automobile major, which will drive optimal vehicle performance, besides extending vehicle longevity, HPCL said at the launch here.

Shares will be allotted in the ratio of 1:3. The rights issue price has been fixed at ₹46 per share, according to a regulatory filing.

Auro Vaccines, a wholly owned step-down subsidiary of the company, terminated the pact with Hilleman Laboratories on Wednesday, Aurobindo Pharma said in a regulatory filing.

The deal with TCS aims to streamline service processes for property owners, enhance retention, and strengthen telecom site partnerships for Vantage Towers across Europe.

It also got approval from the US FDA to manufacture generic leukemia tablets. Furthermore, S&P Global revised Zydus's ESG rating from 77/100 to 78/100.

Following this, the company has appointed Nishant Saigal as the chief financial officer and key managerial personnel of the company, effective from April 14, 2025.